Community-acquired pneumonia: the annual cost to the National Health Service in the UK.
about
Short-course versus long-course therapy of the same antibiotic for community-acquired pneumonia in adolescent and adult outpatientsAntibiotics for community acquired pneumonia in adult outpatientsRespiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trialsBTS Guidelines for the Management of Community Acquired Pneumonia in AdultsStudy of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelinesManagement of Legionella in the intensive care settingReducing door-to-antibiotic time in community-acquired pneumonia: Controlled before-and-after evaluation and cost-effectiveness analysis.Role of oral bacteria in respiratory infection.Patients with community acquired pneumonia admitted to European intensive care units: an epidemiological survey of the GenOSept cohort.Microbial aetiology, outcomes, and costs of hospitalisation for community-acquired pneumonia; an observational analysis.Severity prediction rules in community acquired pneumonia: a validation studyTreatment and outcomes of community-acquired pneumonia at Canadian hospitalsRandomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatmenDo guidelines for community-acquired pneumonia improve the cost-effectiveness of hospital care?Retrospective epidemiological study for the characterization of community- acquired pneumonia and pneumococcal pneumonia in adults in a well-defined area of Badalona (Barcelona, Spain).Rationale and design of the costs, health status and outcomes in community-acquired pneumonia (CHO-CAP) study in elderly persons hospitalized with CAPEarliest innate immune responses require macrophage RelA during pneumococcal pneumonia.Providing better care for patients who may have pneumonia.Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome.The International Community-Acquired Pneumonia (CAP) Collaboration Cohort (ICCC) study: rationale, design and description of study cohorts and patients.Swedish guidelines for the management of community-acquired pneumonia in immunocompetent adults.Hypocapnia and hypercapnia are predictors for ICU admission and mortality in hospitalized patients with community-acquired pneumonia.Recognizing and managing severe community-acquired pneumonia.Improving the 2007 Infectious Disease Society of America/American Thoracic Society severe community-acquired pneumonia criteria to predict intensive care unit admission.Estimated hospitalization rate for diseases attributable to Streptococcus pneumoniae in the Veneto region of north-east ItalyExternal validation of the CURSI criteria (confusion, urea, respiratory rate and shock index) in adults hospitalised for community-acquired pneumonia.Predicting mortality with severity assessment tools in out-patients with community-acquired pneumonia.South African guideline for the management of community-acquired pneumonia in adults.Mortality prediction using serum biomarkers and various clinical risk scales in community-acquired pneumonia.Long-term mortality of hospitalized pneumonia in the EPIC-Norfolk cohort.Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial.Dentures are a Reservoir for Respiratory Pathogens.Multiplex PCR point of care testing versus routine, laboratory-based testing in the treatment of adults with respiratory tract infections: a quasi-randomised study assessing impact on length of stay and antimicrobial useSerum albumin level as a predictor of intensive respiratory or vasopressor support in influenza A (H1N1) virus infection.The usefulness of confusion, urea, respiratory rate, and shock index or adjusted shock index criteria in predicting combined mortality and/or ICU admission compared to CURB-65 in community-acquired pneumonia.Severe community acquired pneumonia.U.K. National COPD Resources and Outcomes Project 2008: patients with chronic obstructive pulmonary disease exacerbations who present with radiological pneumonia have worse outcome compared to those with non-pneumonic chronic obstructive pulmonary dSMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia.Management of community-acquired pneumonia in immunocompetent adults: updated Swedish guidelines 2017.New opportunities for managing acute and chronic lung infections.
P2860
Q24235438-C5220CEA-679D-4F7E-91EE-F44DC8563A44Q24240033-A28C6183-EE93-4CB5-AABE-B89B845F5F08Q24655866-CB69D31A-59D1-4BF6-8B04-46E88558F2BDQ24675547-00FB0826-DB8B-4C82-8558-71EB24E6EFA1Q24679117-C6AC8581-3E44-4A07-833A-A8E9EEAC30DEQ30417993-A7B74C66-7421-406B-880B-103C7279CF18Q30480791-81E59175-3211-4BDA-AFD8-4F3C2976990BQ33707159-70217D07-EB93-4969-92DE-6B73C2BB0E9AQ33752549-01B48022-3D89-42F6-B1B9-BEDA0C1DF083Q33831860-EDF467D9-DF35-491A-B5B9-F4ADF6261568Q33840805-305B78B7-116B-4994-AACD-D91709F0989BQ34037816-B1747153-623F-4EB9-84E6-C7239FE30346Q34108752-592F9BFA-A55A-470A-BEAF-48BE4D93FEF1Q34169255-14A9FF5B-F482-40EB-B4E3-EF25BAE91E05Q34462908-0F94EBCE-A437-4400-96CD-CAF89CFBACC6Q35071890-D798C370-D50B-4792-80BD-C982606FC3CBQ35219857-4A57F71D-2814-4DB1-9F79-DBFE629250FFQ35532824-D6810866-9B95-4BB5-8576-F1CFBA7DECBEQ35536279-0C349ADB-14CD-489E-899A-85A481B1B9BAQ35981786-C0174BD6-2060-41A2-BBB3-B32186D85CADQ36343776-29E8AFF4-AFE5-43B3-BD09-0D32C7CF1A99Q36388035-094BAC19-FAA3-4810-950A-50B40C49DCD0Q36471462-088FE49D-6A68-46C9-8C5F-E4A2AFB5925DQ36767156-75253C61-2384-4404-BBBC-39F1855A812BQ36800391-0DD9FE4B-69EB-471C-95F8-C0E1C8CD17B2Q37515038-8E5FD491-B183-408A-A2A8-B91886C86FCDQ37902371-FB6AC9CA-C313-455E-85AC-332C1BE2F433Q39455917-150FE905-06EF-4D41-B208-C611022910FFQ40147071-8CCF0F54-AB49-4475-BBE2-FE6CC28526F9Q40614570-EB51A9B6-6B78-466E-A219-D7F75D746B6BQ40892792-457E830F-2C57-4F06-8AE5-3542CE91C9ABQ41060301-F184D185-E73E-4096-86CE-CDBB0261E120Q41920031-A6E2D7EC-E028-43C6-9B69-AB21BA994505Q42246504-5D292940-1742-40B0-BC2F-041F1E8CF376Q42583875-6314DE13-2A02-40AE-AEBB-06C1B6F5887FQ42975714-4E8E6739-0C85-4E04-92BB-54D8F50F9DADQ43522201-D8C7D1AA-8B6A-4965-BB81-F3DB6CFB0955Q46536167-14CD1943-48A9-4334-AFA9-87F12C2421F8Q47627293-DC29395E-E275-4399-A2EE-C42B08186380Q47734944-F9A79A8F-A4D1-4BCC-8208-4DE12B57D811
P2860
Community-acquired pneumonia: the annual cost to the National Health Service in the UK.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Community-acquired pneumonia: the annual cost to the National Health Service in the UK.
@en
type
label
Community-acquired pneumonia: the annual cost to the National Health Service in the UK.
@en
prefLabel
Community-acquired pneumonia: the annual cost to the National Health Service in the UK.
@en
P1476
Community-acquired pneumonia: the annual cost to the National Health Service in the UK.
@en
P2093
P304
P356
10.1183/09031936.97.10071530
P577
1997-07-01T00:00:00Z